You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
The company performed 84,067 total tests in Q3 but missed the analysts' average estimates on the top and bottom lines.
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
As a result of the expanded coverage, Natera said it believes there are currently 139 million people covered in the US for average risk NIPT.
For the half year ended Sept. 30, Yourgene booked £8.2 million ($10.7 million) in revenues, up from £7.8 million during the same period last year.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
Natera said that the expanded coverage by Centene will add 24 million people for whom the Panorama noninvasive prenatal test will be covered.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.